|
|
|
Home >
Anti-aging Research > Statins >
Crestor (rosuvastatin)
Crestor (rosuvastatin)
Where to purchase:
Related Topics:
Alternative News:
News & Research:
-
Rosuvastatin Again Linked
With Risks to Kidneys - Medscape, 7/20/22 - "The most potent statin on the
market, rosuvastatin has been linked with excess risk for kidney damage compared
with atorvastatin in case reports and small trials, but there has been little
surveillance of the issue following its approval in 2003 ... Users of
rosuvastatin had an 8% higher risk for hematuria, a 17% higher risk for
proteinuria, and a 15% higher risk for kidney failure with replacement therapy
compared with those on atorvastatin"
-
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels
associated with a significant increase in high-density lipoprotein
cholesterol in patients with coronary artery disease - Atherosclerosis.
2011 Mar 31 - "Atorvastatin significantly decreased
serum ubiquinol (731+/-238 to 547+/-219nmol/L, p=0.001), but rosuvastatin
(680+/-233 to 668+/-299nmol/L, p=0.834) did not" - See
Jarrow
Formulas, Ubiquinol QH-Absorb, 100 mg, 60 Softgels at iHerb.
-
Statins May Soon Be Given to Those With Excess Inflammation - U.S. News,
12/17/09 - "The Food and Drug Administration is
considering expanding the use of cholesterol-lowering statin Crestor to
those who have increased levels of inflammation—but not high cholesterol ...
2.8 percent of folks in the Crestor group developed diabetes compared with
2.3 percent of those who took placebos ... Experts still can't explain why
Crestor would increase the likelihood of diabetes, but other research
suggests that the entire class of statin drugs appears to have this downside
... found a 13 percent increased risk in diabetes in the statin users ...
1.5 percent of the placebo takers had a heart attack or stroke compared with
0.72 percent of the statin takers"
-
Rosuvastatin Nearly Cuts in Half Risk of Stroke - Doctor's Guide,
2/20/09 - "A refined analysis of a major clinical
trial indicates that treating patients with the cholesterol-lowering agent
rosuvastatin dramatically reduces the incidence of stroke among patients
with high levels of C-reactive protein when compared with patients taking
placebo ... Patients in the study were randomised to rosuvastatin 20 mg
daily or placebo"
-
More May Benefit From Cholesterol Drugs - WebMD, 1/13/09 -
"Eight out of 10 middle-aged and older Americans may
benefit from treatment with cholesterol-lowering statin drugs ... All the
participants had elevated levels of high-sensitivity C-reactive protein
(hsCRP) ... Over an average of two years of treatment, participants who took
the statin Crestor had half as many heart attacks, strokes, and deaths from
cardiovascular causes as participants randomly assigned to receive a
placebo"
-
JUPITER hits New Orleans: Landmark study shows statins benefit healthy
individuals with high CRP levels - theheart.org, 11/9/08 -
"In a study of individuals with low LDL cholesterol
but elevated C-reactive-protein (CRP) levels, investigators showed that
rosuvastatin (Crestor, AstraZeneca) 20 mg significantly reduced the primary
end point—a composite of nonfatal MI, nonfatal stroke, hospitalization for
unstable angina, revascularization, and confirmed death from cardiovascular
causes—by 44% compared with individuals treated with placebo" -
Note: They seem to be attributing this to the reduction in CRP. At 12
months, the CRP of the 20 mg Crestor group was 2.2. The baseline was 4.2.
That's a (4.2 - 2.2)/4.2 = 47.6% reduction in CRP. Another option to reduce
CRP might be Periostat (low dose doxycycline for periodontal disease). See
my
CRP page for other ways to reduce it. See:
-
Low-dose Periostat (Doxycycline) Shows Benefits in Patients with Heart
Failure - Doctor's Guide, 11/20/02 -
"At six-month follow-up, sub-antimicrobial dose
doxycyline significantly reduced
CRP levels by
45.8 percent compared to baseline values (p<0.05). The drug was also
associated with a 33.5 percent reduction in interleukin-6 and a 50
percent reduction in metalloproteinase ... The findings are exciting,
since research is now showing that CRP is both a key marker of
inflammation leading to future acute coronary events, but also that CRP
itself may contribute to the initiation and progression of
atherosclerosis"
-
No Efficacy Benefits Seen With Rosuvastatin Against Placebo in GISSI-HF
Trial of Symptomatic Chronic Heart Failure - Doctor's Guide, 9/2/08 -
"At a median follow-up of 3.9 years, the researchers
found no difference in results for time to all-cause mortality, Dr. Tognoni
said, with 28.1% for placebo and 28.8% for rosuvastatin and an adjusted
hazard ratio (aHR) of 1.00 (P = .943). All-cause mortality or
hospitalisation for cardiovascular reasons also showed no difference, at
56.1% and 57.1%, respectively"
-
Statin Drug Crestor Slows Artery Plaque - WebMD, 4/1/08 -
"A trial of the statin drug Crestor [rosuvastatin]
has been halted early due to "unequivocal evidence" that it reduces heart
attacks, strokes, and deaths due to cardiovascular disease in people with no
signs of heart disease" - See rosuvastatin at
OffshoreRx1.com.
-
Crestor May Not Cut Heart Failure Death - WebMD, 11/28/07
-
New Crestor(R) (rosuvastatin calcium) Indication Approved in U.S. to Slow
Progression of Atherosclerosis in Patients With High Cholesterol -
Doctor's Guide, 11/15/07 - "The U.S. Food and Drug
Administration (FDA) has approved Crestor(R) (rosuvastatin calcium) as an
adjunct to diet to slow the progression of atherosclerosis in patients with
elevated cholesterol"
-
Carotid Artery Thickening Slowed With Rosuvastatin Therapy - Doctor's
Guide, 11/8/07 - "228 patients on rosuvastatin with
less than two risk factors for heart disease and thinner carotid intima
showed a progression of thickness growth at the rate of.0007 mm/year, while
the average growth in thickness among the 76 placebo patients was.0123
mm/year, a difference that was statistically significant"
-
CORONA: Little Clinical Benefit Seen in First Major Statin Trial in HF -
Medscape, 11/6/07 - "Over a median follow-up of 33
months, there were no significant differences in the primary end point or in
all-cause mortality, the rate of coronary events (which included sudden
death, fatal or nonfatal MI, percutaneous coronary intervention [PCI] or
coronary arterial bypass graft [CABG], resuscitated cardiac arrest, and
hospitalization for unstable angina), effects on NYHA class, or the rate of
newly diagnosed diabetes ... Despite the lack of difference in the primary
end point, there were significant reductions in levels of CRP; however, they
were not decreased to what would be considered a low level ... This does
bring into question whether higher doses of rosuvastatin could have
additional clinical benefit" - Note: Statins do little to increase
HDL which some studies imply may be more important. Also, statins have been
shown to decrease co-enzyme Q10. I would have liked to see the results if
they had added niacin to increase HDL and co-enzyme Q10.
-
Crestor Halts Artery Thickening - WebMD, 3/26/07 -
"in people on Crestor, the thickness of the artery
wall dropped by 0.0014 millimeters a year. In contrast, it thickened by
about 0.013 millimeters per year in those on placebo"
-
New EXPLORER Results Show Patients Achieved Dramatic Reductions in
C-Reactive Protein And LDL-C Levels With Rosuvastatin Combination Therapy
- Doctor's Guide, 9/6/06
-
Biggest LDL-C Reduction Ever Shown in Patients Is Achieved With
Rosuvastatin/Ezetimibe Combination - Doctor's Guide, 6/20/06
-
New Study Showed Ezetimibe/Simvastatin Significantly More Effective Than
Rosuvastatin at Lowering LDL Cholesterol at all Doses Compared -
Doctor's Guide, 6/19/06
-
Rosuvastatin: An Independent Analysis of Risks and Benefits - Medscape,
6/14/06
-
Rosuvastatin Helped More Patients Reach Goal in MERCURY II Study -
Doctor's Guide, 5/15/06
-
Intensive Statin Therapy Useful in High-Risk Coronary Patients -
Doctor's Guide, 3/13/06 - "very high-intensity
statin therapy using rosuvastatin 40 mg/day induces regression of coronary
atherosclerosis ... treatment decreased LDL-C to 60.8 mg/dL while increasing
HDL-C by 14.7%"
-
Statins May Reverse Plaque Buildup
- WebMD, 3/13/06
-
New Data Examines Effects of Crestor Alone or in Combination with Another
Therapy in High Risk Patients with Very High Cholesterol - Doctor's
Guide, 11/22/05
-
Rosuvastatin Appears Safe and Effective for Treating Hyperlipidemia in
Diabetic Patients with Chronic Kidney Disease - Doctor's Guide, 11/11/05
-
Direct Comparison Shows Rosuvastatin Achieves Greater Reductions than
Atorvastatin in LDL-C - Doctor's Guide, 10/27/05
-
Crestor (Rosuvastatin) May Be Associated With Arrested Progression of
Atherosclerosis and Regression of Plaques at Sites With The Most Disease
- Doctor's Guide, 5/6/05
- FDA warns of risks from
AstraZeneca’s Crestor - MSNBC, 3/2/05
-
Crestor (Rosuvastatin) Appears To Helps More African-American Patients
Achieve Cholesterol Goals - Doctor's Guide, 11/16/04
-
Rosuvastatin Provides Better Rates of Lipid Lowering Compared to Other
Statins - Doctor's Guide, 10/27/04 -
"switching to rosuvastatin from another statin agent
helped more patients achieve primary treatment goals for low-density
lipoprotein cholesterol (LDL-C) and secondary apolipoprotein
(apo) B
treatment goals in coronary heart disease (CHD) patients with high lipid
levels"
-
Rosuvastatin Shows Better Results in Lipid Parameters Among Diabetic
Patients - Doctor's Guide, 10/25/04
-
Rosuvastatin May Be Better Than Atorvastatin in Patients With Metabolic
Syndrome - Doctor's Guide, 10/25/04 -
"The benefits of rosuvastatin were seen in levels of
low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), apoprotein (apo) A-I and apo B, total cholesterol and
non-HDL-C"
- Cholesterol
Drug Safety Questioned - WebMD, 5/18/04 -
"a citizen group has renewed its call for the FDA to
ban the cholesterol-lowering drug Crestor ... there have been 11 new cases
of the muscle-destroying condition -- rhabdomyolysis -- and three additional
cases of kidney damage in people taking Crestor"
- Statins Effectively
Lower Cholesterol, But Experts Debate First Choice - Medscape, 3/15/04 -
"HDL cholesterol levels were increased more than 10%
with rosuvastatin 40 mg, nearly 5% with
atorvastatin 80 mg, 10% with 40 mg
simvastatin, and 6.4% with 40 mg
pravastatin"
-
Rosuvastatin Lowers Cholesterol Most in Metabolic Syndrome Patients -
Doctor's Guide, 3/10/04 -
"In a comparison of 4 cholesterol-lowering drugs,
rosuvastatin (Crestor) resulted in the greatest reductions in low-density
lipoprotein (LDL) cholesterol ... rosuvastatin also was better than the
other statins in raising high density lipoprotein [HDL] cholesterol and in
lowering triglycerides"
- Group Asks FDA
to Ban Cholesterol Drug - WebMD, 3/5/04
-
Group seeks ban of latest statin because of muscle side effect - USA
Today, 3/4/04 -
"A 39-year-old woman has died of a muscle-destroying
condition linked to the controversial new anti-cholesterol drug
Crestor ... Crestor also was linked to some cases of kidney
abnormalities not seen with other statins"
- Lancet Takes Aim at
Rosuvastatin in Blistering Editorial - Medscape, 10/23/03 -
"More than 80% of patients reach their [low-density
lipoprotein cholesterol] goals on the starting dose of 10 mg, which also
significantly increases [high-density lipoprotein cholesterol], a profile
unmatched by competitor drugs ... Dr Horton added that there is no evidence
to support prescribing rosuvastatin over "simvastatin
or
atorvastatin ... The FDA approved the drug in August at 5-, 10-, and
20-mg doses. An 80-mg dose application was withdrawn by AstraZeneca because
of safety concerns about increased risk of
rhabdomyolysis,
which was the same adverse effect that triggered the withdrawal of Bayer's
cerivastatin (Baycol) in 2001. In the Lancet editorial, Dr. Horton wrote
that some critics raise similar criticisms about rosuvastatin at the 40-mg
dose, which the FDA approved under restricted distribution. He noted in the
interview with Medscape that Public Citizen, a U.S. consumer watchdog group
affiliated with Ralph Nader, has issued a "Do Not Use" warning about
rosuvastatin"
-
Study Confirms Benefit Of New Statin, Crestor (Rosuvastatin), In 'Real Life
Setting - Doctor's Guide, 10/8/03 -
"substantially more patients (more than three
quarters) achieved the recommended NSF for CHD cholesterol targets1 when
treated with rosuvastatin compared to other statins"
-
Rosuvastatin Improves Plasma Lipid Ratios - Doctor's Guide, 10/1/03 -
"Rosuvastatin
significantly more effective than
atorvastatin, simvastatin, and
pravastatin in improving the ratios of total cholesterol to high-density
lipoprotein cholesterol" - See
Crestor (rosuvastatin)
at drugstore.com.
-
Rosuvastatin 10-40 mg Safe and Well Tolerated Compared to Other Statins
- Doctor's Guide, 10/1/03 -
"Minor adverse events associated with the use of
rosuvastatin included myalgia in 2.1%, asthenia in 1.2%, nausea in 1.4%,
dyspepsia in 0.6%, headache in 1.1%, insomnia in 0.8%, abdominal pain in
1.2%, diarrhoea in 1.1%, constipation in 1.1%, and flatulence in 0.9%"
-
Rosuvastatin Improves Apolipoprotein Levels - Doctor's Guide, 10/1/03
-
Crestor (Rosuvastatin Calcium) Available in US For Treatment of Elevated
Cholesterol - Doctor's Guide, 9/16/03 -
"Crestor is available in 5 to 40 mg doses in
pharmacies nationwide ... In clinical trials, Crestor lowered LDL
(low-density lipoprotein) cholesterol or "bad" cholesterol by 45 to 63
percent (7 percent for placebo) and increased HDL (high-density lipoprotein)
cholesterol or "good" cholesterol by 8 to 14 percent (3 percent for
placebo)"
-
Heart Protection Study Implications for Lipid Management Guidelines and
Practices - Doctor's Guide, 9/16/03 -
"While Heart Protection Study (HPS) findings support
aggressive lowering of low-density lipoprotein (LDL) cholesterol levels and
suggest optimal levels well below current recommendations, failure to
achieve current goals for LDL cholesterol is common ... HPS findings
demonstrated that a reduction of major vascular events extended even to CAD
patients with initial LDL cholesterol levels <100 mg/dL using simvastatin 40
mg, suggesting that the optimal LDL cholesterol level is below target levels
established in current guidelines ... rosuvastatin is more effective than
other statins in reducing LDL cholesterol"
-
Cholesterol-Lowering Statin, Crestor (Rosuvastatin Calcium), Receives FDA
Approval - Doctor's Guide, 8/13/03
-
FDA Advisory Committee Unanimously Recommends Approval of Lipid Lowering
Drug, Crestor (Rosuvastatin Calcium) - Doctor's Guide, 7/10/03
-
Rosuvastatin Improves Metabolic Syndrome Risk Factors - Doctor's Guide,
4/9/03
-
Rosuvastatin Achieves LDL-C Goal When Other Statins Fall Short -
Doctor's Guide, 4/1/03
-
Rosuvastatin More Effective Than Atorvastatin In Hypercholesterolemic
Patients - Doctor's Guide, 2/13/02
- Crestor (Rosuvastatin)
Superior Impact On Lipid Levels Confirmed - Doctor's Guide, 9/3/01
- New Drug
[rosuvastatin] Takes a Sledgehammer to High Cholesterol - WebMD, 3/20/01
Abstracts:
Related Searches:
70702
|
|
